Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Traws Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Traws Pharma's regulatory disclosures and financial reporting.
Traws Pharma director Clarke Trafford received a new stock option grant as part of his compensation. He was awarded options for 33,435 shares of common stock at an exercise price of $1.60 per share. These options were granted under the company’s 2021 Incentive Compensation Plan by the independent compensation committee and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Trafford holds 33,435 stock options directly, which are scheduled to expire on March 8, 2036.
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options as compensation. He was awarded 31,258 options to buy common stock at an exercise price of $1.6000 per share. These options vest 100% on the first anniversary of the March 8, 2026 grant, and his reported derivative holdings after the grant are 31,258 options.
Traws Pharma director John Harold Leaman received a stock option grant for 33,435 shares of common stock. The options have an exercise price of $1.60 per share and were awarded at no upfront cost as compensation. According to the award terms, the options will vest 100% on the first anniversary of the March 8, 2026 grant date, after which they become exercisable. Following this grant, Leaman holds 33,435 stock options directly.
Traws Pharma, Inc. granted Chief Executive Officer Iain D. Dukes stock options covering 231,336 shares of common stock. The options have a $1.60 exercise price, were awarded at no cost, and will vest 100% on the first anniversary of the March 8, 2026 grant date. They expire on March 8, 2036 and represent compensation approved by the company’s independent compensation committee under its 2021 Incentive Compensation Plan, rather than an open-market share purchase or sale.
Traws Pharma, Inc. reported that Chief Science Officer Virology Charles David Pauza received a grant of 118,367 stock options to buy common stock at an exercise price of $1.6000 per share. These options were awarded by the compensation committee under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the March 8, 2026 grant date. Following this award, Pauza holds 118,367 options directly, and the options are scheduled to expire on March 8, 2036.
Traws Pharma, Inc. reported that its Chief Operating Officer, Nikolay Savchuk, received a grant of stock options as part of his compensation. He was awarded 96,899 stock options to buy common shares at an exercise price of $1.60 per share, expiring on March 8, 2036. These options were granted under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the grant date, meaning they become fully exercisable after one year. Following this grant, he holds 96,899 options, and there were no open‑market purchases or sales reported in this filing.
Traws Pharma, Inc. reported that director Jack E. Stover received a grant of stock options covering 33,435 shares of common stock. The options have an exercise price of $1.6000 per share and were awarded under the company’s 2021 Incentive Compensation Plan. They will vest 100% on the first anniversary of the March 8, 2026 grant date, giving Stover the right to buy the full amount after one year if he chooses to exercise.
Traws Pharma, Inc. reported that Chief Medical Officer Robert Redfield received a grant of stock options covering 108,854 shares of common stock. These options have an exercise price of $1.6000 per share and were awarded under the company’s 2021 Incentive Compensation Plan.
The options will vest 100% on the first anniversary of the March 8, 2026 grant date, and expire on March 8, 2036. Following this award, Redfield holds options for 108,854 underlying shares, reflecting a compensation-related acquisition rather than an open‑market trade.
Traw Pharma, Inc. director Mary Teresa Shoemaker reported a grant of stock options as equity compensation. She received options covering 33,435 shares of common stock with an exercise price of $1.6000 per share, awarded by the company’s compensation committee under its 2021 Incentive Compensation Plan.
The options will vest 100% on the first anniversary of the 2026-03-08 grant date and expire on 2036-03-08. Following this award, Shoemaker holds 33,435 stock options directly.
Traws Pharma, Inc. filed an 8-K after completing analysis of a 90-patient, open-label Phase 2 study of oral ratutrelvir versus PAXLOVID® in mild-to-moderate COVID-19, including a PAXLOVID®-ineligible arm. PAXLOVID®-ineligible patients on ratutrelvir reported fewer treatment-related adverse events (10% vs 23.3%) and faster symptom resolution (HR 1.31; 95% CI 0.78–2.20; p=0.018), with no viral rebound observed in ratutrelvir-treated patients.
The company also reported that a tablet formulation of tivoxavir marboxil increased exposure by 30% versus a prototype, with modeling suggesting 28-day influenza protection and plans for a prophylaxis challenge study. Separately, the FDA placed the U.S. IND for tivoxavir marboxil on clinical hold over mutagenicity data, with formal feedback expected by March 16, 2026.